Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2713
-0.0037 (-1.35%)
Nov 14, 2025, 4:00 PM EST - Market closed
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,190,409
Market Cap
9.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | 0 | - |
| Dec 31, 2023 | 22 | 1 | 4.76% |
| Dec 31, 2022 | 21 | 5 | 31.25% |
| Dec 31, 2021 | 16 | 6 | 60.00% |
| Dec 31, 2020 | 10 | -1 | -9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TOVX News
- 22 days ago - Theriva Biologics Provides Response to Unusual Market Action - GlobeNewsWire
- 4 weeks ago - Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 6 months ago - Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Pricing of $7.5 Million Public Offering - GlobeNewsWire
- 7 months ago - Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - GlobeNewsWire